{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:10:01Z","timestamp":1756375801599,"version":"3.44.0"},"reference-count":8,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,8,16]]},"abstract":"<jats:p>A 26-year-old Japanese man was admitted to our unit with exacerbated paranoid schizophrenia. Prior to his admission, daily administration of olanzapine had been sufficient to maintain a partial remission of his schizophrenia, but due to an exacerbation of his delusions, he had then also been prescribed aripiprazole, which had been followed by no improvement in symptoms and a gradual further exacerbation of auditory delusions. Physical examinations, brain MRI and neurophysiological assessment were unremarkable. Blood analysis, however, revealed extremely low thyroid-stimulating hormone (TSH) and prolactin-releasing hormone (PRL) concentration. Interestingly, after aripiprazole discontinuation, he returned to partial remission with an increase in plasma TSH and PRL concentration.<\/jats:p>","DOI":"10.1136\/bcr-2017-220192","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T08:50:28Z","timestamp":1503391828000},"page":"bcr-2017-220192","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["TSH and PRL, side-effect markers in aripiprazole treatment: adjunctive aripiprazole-induced thyrotropin oversuppression in a young man with schizophrenia"],"prefix":"10.1136","volume":"2017","author":[{"given":"Hidenobu","family":"Ohta","sequence":"first","affiliation":[{"name":"Department of Psychophysiology, National Institute of Mental health, National Center of Neurology and Psychiatry, Kodaira, Japan"},{"name":"Department of Psychiatry, Asai Hospital, Togane, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asai Hospital, Togane, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asai Hospital, Togane, Japan"},{"name":"Department of Cognitive Behavioral Physiology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asai Hospital, Togane, Japan"},{"name":"Department of Psychology, Kawamura Gakuen Woman's University, Abiko, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106071334"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830150047009"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JCP.0000000000000527","article-title":"Aripiprazole-associated hypoprolactinemia in the clinical setting","volume":"36","author":"Sogawa","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3371\/CSRP.PRJA.022015","article-title":"Aripiprazole-induced hypoprolactinemia in an adult male with first-episode psychosis","volume":"9","author":"Propst","year":"2016","journal-title":"Clin schizophr relat psychoses"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.5","doi-asserted-by":"crossref","unstructured":"Pivonello R , Waaijers M , Kros JM , et al . Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. Endocrine 2017;57.doi:10.1007\/s12020-016-1107-2","DOI":"10.1007\/s12020-016-1107-2"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.6","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1150419"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0006-291X(73)91344-2","article-title":"Further evidence that TRH is also a physiological regulator of PRL secretion in man","volume":"51","author":"Bowers","year":"1973","journal-title":"Biochem Biophys Res Commun"},{"key":"2025082802294525000_2017.aug22_1.bcr-2017-220192.8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM197112022852302","article-title":"Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man","volume":"285","author":"Anderson","year":"1971","journal-title":"N Engl J Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-220192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:29:55Z","timestamp":1756373395000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-220192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":8,"alternative-id":["10.1136\/bcr-2017-220192"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-220192","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,8,22]]}}}